Announcement.
WEBINAR: No more missed pathogens. One metagenomic method for all.
REGISTER NOW
Enzymes that Unlock
Your Next Discovery
0
Resources
Company
Contact
X

Essential insights based on 3rd party publications:

Get the White Paper now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

Quantification Challenges of Chromatin — Associated Host Cell DNA:
An Underestimated Risk

  • Discover why host cell DNA quantities are often significantly underestimated.
  • Understand the limitation of conventional nucleases when degrading chromatin

Download the poster here
and get access to the
interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Investors News

Joint Research with Austrian Centre of Industrial Biotechnology

Apr 9, 2024

Tromsø, Norway, April 9, 2024 - ArcticZymes Technologies ASA (OSE: AZT) and the Austrian Centre of Industrial Biotechnology (acib) enter a joint research project to uncover the benefits of salt active nucleases in the purification of bionanoparticles (BNP’s).

Read More
Read More

Research Paper on ArcticZymes R2D Ligase Published in the Biotechnology Journal

Mar 27, 2024

Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT) Research Paper on ArcticZymes R2D Ligase™ is published in the Biotechnology Journal

Read More
Read More

ArcticZymes Technologies ASA Q4 2023 Results & Presentation

Feb 1, 2024

Tromsø, Norway, February 1st, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.4 million and an EBITDA of NOK 2.0 million for the fourth quarter of 2023.

Read More
Read More

New Product Launch - SAN HQ GMP

Jan 30, 2024

Tromsø, Norway, January 30th, 2024 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP).

Read More
Read More